Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.

Wardhana, Datau EA, Rotty LW, Haroen H.

Acta Med Indones. 2011 Oct;43(4):252-9. Review.

2.

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.

Tefferi A.

Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Review. Erratum in: Am J Hematol. 2013 May;88(5):437-45.

3.

Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.

El Fakih R, Popat U.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S34-42. doi: 10.1016/j.clml.2015.02.034. Review.

PMID:
26297276
4.

[Primary myelofibrosis--pathogenesis, diagnosis and treatment].

Ghanima W, Knutsen H, Delabie J, Bruserud Ø.

Tidsskr Nor Laegeforen. 2013 Oct 1;133(18):1946-50. doi: 10.4045/tidsskr.12.1106. Review. Norwegian.

5.

Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.

DeLario MR, Sheehan AM, Ataya R, Bertuch AA, Vega C 2nd, Webb CR, Lopez-Terrada D, Venkateswaran L.

Am J Hematol. 2012 May;87(5):461-4. doi: 10.1002/ajh.23140. Epub 2012 Mar 3.

6.

Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.

Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D.

Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72. Review.

7.

Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.

Hogan WJ, Litzow MR, Tefferi A.

Curr Hematol Malig Rep. 2007 Feb;2(1):34-42. doi: 10.1007/s11899-007-0005-3. Review.

PMID:
20425386
8.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

9.

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.

Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM; MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

Exp Hematol. 2007 Nov;35(11):1719-22.

PMID:
17976523
10.

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S, Deeg HJ.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1274-81. doi: 10.1016/j.bbmt.2014.03.017. Epub 2014 Mar 27. Review.

11.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Barosi G, Bacigalupo A.

Curr Opin Hematol. 2006 Mar;13(2):74-8. Review.

PMID:
16456372
12.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H; IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Blood. 2006 Sep 1;108(5):1497-503. Epub 2006 May 4. Review.

13.

Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders.

Castro-Malaspina H, Gay RE, Jhanwar SC, Hamilton JA, Chiarieri DR, Meyers PA, Gay S, Moore MA.

Blood. 1982 May;59(5):1046-54.

14.

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.

Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR, Kröger N.

Bone Marrow Transplant. 2010 Sep;45(9):1404-7. doi: 10.1038/bmt.2009.367. Epub 2010 Jan 11.

PMID:
20062088
15.

Physician Education: Myelodysplastic Syndrome.

Yoshida Y.

Oncologist. 1996;1(4):284-287.

16.

Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.

Dingli D, Mesa RA, Tefferi A.

Intern Med. 2004 Jul;43(7):540-7. Review.

17.

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.

Mesa RA, Quintás-Cardama A, Verstovsek S.

Curr Hematol Malig Rep. 2007 Feb;2(1):25-33. doi: 10.1007/s11899-007-0004-4. Review.

PMID:
20425385
18.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL.

Blood. 2010 Apr 8;115(14):2919-27. doi: 10.1182/blood-2009-04-218842. Epub 2010 Feb 12.

19.

Allogeneic stem cell transplantation as treatment for myelofibrosis.

Papageorgiou SG, Castleton A, Bloor A, Kottaridis PD.

Bone Marrow Transplant. 2006 Dec;38(11):721-7. Epub 2006 Oct 2. Review.

PMID:
17013423
20.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.

Kekre N, Ho VT.

Am J Hematol. 2016 Jan;91(1):123-30. doi: 10.1002/ajh.24215. Epub 2015 Nov 17. Review.

Supplemental Content

Support Center